Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbott Laboratories (ABT) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 78,451,200
  • Shares Outstanding, K 1,728,000
  • Annual Sales, $ 20,853 M
  • Annual Income, $ 1,400 M
  • 36-Month Beta 0.97
  • Price/Sales 3.73
  • Price/Cash Flow 16.14
  • Price/Book 3.74

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.25 +15.67%
on 01/25/17
45.51 -0.24%
on 02/23/17
+5.06 (+12.54%)
since 01/23/17
3-Month
37.38 +21.46%
on 12/01/16
45.51 -0.24%
on 02/23/17
+6.42 (+16.47%)
since 11/23/16
52-Week
36.76 +23.50%
on 06/27/16
45.79 -0.85%
on 08/02/16
+7.01 (+18.26%)
since 02/23/16

Most Recent Stories

More News
Abbott Commences Exchange Offers and Consent Solicitations for St. Jude Medical, LLC Notes

Abbott (NYSE:ABT) announced today that it has commenced offers to exchange all validly tendered and accepted notes of the following series issued by St. Jude Medical, LLC (successor to St. Jude Medical,...

ABT : 45.40 (+0.87%)
STJ : 80.82 (+0.16%)
Abbott Declares 373rd Consecutive Quarterly Dividend

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share.

ABT : 45.40 (+0.87%)
Medical Microbiology Testing Technologies Market to be Worth US$3.4 Bn by 2024: Demand for Automation in Microbiology Research Assures Growth, Notes TMR

Transparency Market Research points out that the leading players operating in the Global Medical Microbiology Testing Technologies Market Abbott Laboratories, Agilent Technologies, Becton, Dickinson and...

A : 51.47 (+0.25%)
ABT : 45.40 (+0.87%)
U.S. FDA Grants Abbott the First Commercial Authorization for a Molecular Test to Detect Zika Virus Using Whole Blood

Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has authorized its molecular test, the Abbott RealTime ZIKA test, to detect Zika virus in whole blood (when collected...

ABT : 45.40 (+0.87%)
Abbott Announces U.S. Approval for its Assurity MRI(TM) Pacemaker, the World's Smallest, Longest-Lasting Wireless MRI-Compatible Pacemaker

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for both the Assurity MRI(TM) pacemaker and the Tendril(TM) MRI pacing...

ABT : 45.40 (+0.87%)
Blood Glucose Device Market & Forecast (SMBG) (Test Strips, Lancet, Meter) - Worldwide Analysis

Self-Monitoring Blood Glucose (SMBG) Device Market is expected to cross over US$ 16 Billion by 2020 as incidence of diabetes is increasing dramatically. It is estimated that 642 Million people will develop...

ABT : 45.40 (+0.87%)
Worldwide Bio MEMS Market is Estimated to Surge at a CAGR of 20.9% by 2024; High Prevalence of Heart Diseases Gives Impetus to Cardio-MEMS| TMR

ALBANY, New York, January 27, 2017 /PRNewswire/ --

ABT : 45.40 (+0.87%)
MDT : 80.74 (+1.41%)
Worldwide Bio MEMS Market is Estimated to Surge at a CAGR of 20.9% by 2024; High Prevalence of Heart Diseases Gives Impetus to Cardio-MEMS| TMR

Transparency Market Research has observed the competitive landscape in the global bio-MEMS market to be quite consolidated. The top five players held a whopping share of about 45% in the global market...

ABT : 45.40 (+0.87%)
MDT : 80.74 (+1.41%)
J&J to spend $30 billion on Swiss drugmaker Actelion

Johnson & Johnson will buy Swiss drugmaker Actelion in a $30 billion deal that both secures promising research and bolsters the product portfolio controlled by the U.S. health care giant.

ABT : 45.40 (+0.87%)
JNJ : 121.70 (+1.82%)
PFE : 34.06 (+1.40%)
ALIOY : 66.9950 (-0.25%)
Q4 Scorecard and Analyst Reports for Texas Instruments & Lockheed Martin

Q4 Scorecard and Analyst Reports for Texas Instruments & Lockheed Martin

LMT : 264.85 (-0.40%)
ABT : 45.40 (+0.87%)
YHOO : 45.41 (-1.24%)
HPQ : 17.60 (+8.64%)
TXN : 77.14 (-0.12%)
CNI : 71.19 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

See More

Support & Resistance

2nd Resistance Point 45.91
1st Resistance Point 45.66
Last Price 45.40
1st Support Level 45.00
2nd Support Level 44.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.